https://mindmedicinelaw.com/briefing/psilocybin-adverse-effects-in-cyclothymia-clinical-and-policy-lessons-20260930-45650The Psychedelic Journalen2026-09-30T22:07:05.261616+00:00Psilocybin Adverse Effects in Cyclothymia: Clinical and Policy Lessonspsilocybin, cyclothymia, mood disorders, adverse effects, clinical trial screening, psychedelic research, risk management, policy implications, mental healthhttps://mindmedicinelaw.com/briefing/va-launches-psilocybin-study-for-veterans-policy-and-research-implications-in-th-20260930-45662The Psychedelic Journalen2026-09-30T22:06:54.084970+00:00VA Launches Psilocybin Study for Veterans: Policy and Research Implications in the USva psilocybin study, veterans mental health, psychedelic research policy, independent research funding, federal clinical trials, ptsd depression treatment, schedule i regulation, data transparency, us psychedelic sciencehttps://mindmedicinelaw.com/briefing/dea-schedule-i-proposal-for-fda-breakthrough-postpartum-depression-drug-20260930-45660The Psychedelic Journalen2026-09-30T22:05:06.687456+00:00DEA Schedule I Proposal for FDA Breakthrough Postpartum Depression Drugdea schedule i, postpartum depression, breakthrough therapy, fda, psychedelic research, clinical trials, controlled substances act, drug policy, research barriers, mental health innovationhttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-for-depression-in-lung-cancer-patients-us-2026-20260930-45500The Psychedelic Journalen2026-09-30T15:04:30.513468+00:00Psilocybin Clinical Trial for Depression in Lung Cancer Patients (US, 2026)psilocybin, lung cancer, depression, clinical trial, oncology, palliative care, psychedelic therapy, FDA, insurance coverage, mental healthhttps://mindmedicinelaw.com/briefing/evaluating-psychedelic-harm-reduction-new-framework-for-event-settings-20260929-45551The Psychedelic Journalen2026-09-30T22:05:38.818260+00:00Evaluating Psychedelic Harm Reduction: New Framework for Event Settingspsychedelic harm reduction, event health infrastructure, zendo project, peer support, public health policy, mixed-methods evaluation, non-clinical psychedelic use, framework development, safety at festivals, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-vs-ect-for-severe-depression-meta-analysis-shifts-clinical-debate-20260929-45595The Psychedelic Journalen2026-09-30T22:05:22.277062+00:00Ketamine vs ECT for Severe Depression: Meta-Analysis Shifts Clinical Debateketamine, electroconvulsive therapy, treatment-resistant depression, meta-analysis, neurocognitive outcomes, clinical guidelines, psychiatry, policy, payer decisionshttps://mindmedicinelaw.com/briefing/calgary-launches-psychedelic-ptsd-trial-for-partner-violence-survivors-20260929-45400The Psychedelic Journalen2026-09-29T22:04:40.494825+00:00Calgary Launches Psychedelic PTSD Trial for Partner Violence Survivorscalgary psychedelic trial, ptsd partner violence, canada mental health policy, psychedelic-assisted therapy, trauma research, clinical trial canada, health canada special access program, ethical considerations psychedelics, public health trauma, complex ptsd treatmenthttps://mindmedicinelaw.com/briefing/filament-s-pex010-powers-phase-2-psilocybin-ptsd-trial-in-canada-20260929-45237The Psychedelic Journalen2026-09-29T15:04:59.050086+00:00Filament’s PEX010 Powers Phase 2 Psilocybin PTSD Trial in Canadafilament health, pex010, psilocybin, ptsd clinical trial, university of calgary, health canada, gmp-grade psychedelics, canadian psychedelic policy, industry-academic collaboration, psychedelic therapy regulationhttps://mindmedicinelaw.com/briefing/student-mobilization-after-fda-psychedelic-hearing-policy-impact-20260929-45238The Psychedelic Journalen2026-09-29T15:04:45.840616+00:00Student Mobilization After FDA Psychedelic Hearing: Policy Impactfda hearing, psychedelic therapies, student advocacy, drug policy reform, public comment, clinical trial access, regulatory frameworks, grassroots mobilization, equity in research, community oversighthttps://mindmedicinelaw.com/briefing/emergency-management-of-emerging-synthetic-drug-intoxications-20260928-45553The Psychedelic Journalen2026-09-30T22:07:16.571963+00:00Emergency Management of Emerging Synthetic Drug Intoxicationsemerging synthetic drugs, emergency medicine, toxidrome recognition, psychiatric complications, synthetic cannabinoids, synthetic cathinones, nitazenes, xylazine, clinical toxicology, integrated carehttps://mindmedicinelaw.com/briefing/systematic-review-anti-inflammatory-effects-of-psychedelics-in-preclinical-model-20260928-45584The Psychedelic Journalen2026-09-30T22:06:25.787984+00:00Systematic Review: Anti-Inflammatory Effects of Psychedelics in Preclinical Modelspsychedelics, anti-inflammatory effects, systematic review, serotonergic psychedelics, preclinical models, human trials, immunomodulation, cytokines, clinical trial design, translational researchhttps://mindmedicinelaw.com/briefing/rapid-acting-and-neuromodulatory-ocd-treatments-psilocybin-and-beyond-20260928-45585The Psychedelic Journalen2026-09-30T22:06:12.692672+00:00Rapid-Acting and Neuromodulatory OCD Treatments: Psilocybin and Beyondpsilocybin, ketamine, treatment-resistant ocd, neuromodulation, rTMS, deep brain stimulation, stress pathways, clinical trials, regulatory status, biomarkershttps://mindmedicinelaw.com/briefing/persistent-perceptual-abnormalities-in-psychedelic-users-new-insights-from-senso-20260928-45552The Psychedelic Journalen2026-09-30T22:05:56.984922+00:00Persistent Perceptual Abnormalities in Psychedelic Users: New Insights from Sensory Processing Researchpersistent perceptual abnormalities, psychedelic research, sensory processing, conditioned hallucinations, clinical trial risk, public health policy, decision precision, visual discrimination, psilocybin, LSDhttps://mindmedicinelaw.com/briefing/post-psychedelic-difficulties-meta-aggregation-insights-for-counselling-practice-20260927-45287The Psychedelic Journalen2026-09-29T22:04:52.131766+00:00Post-Psychedelic Difficulties: Meta-Aggregation Insights for Counselling Practicepost-psychedelic difficulties, harm reduction, counselling practice, integration support, non-clinical psychedelic use, meta-aggregation, user experiences, public health policy, psychological distress, pluralistic approacheshttps://mindmedicinelaw.com/briefing/network-analysis-of-ketamine-in-trd-pooled-rct-insights-2026-20260926-45338The Psychedelic Journalen2026-09-29T22:05:04.422355+00:00Network Analysis of Ketamine in TRD: Pooled RCT Insights (2026)ketamine, treatment-resistant depression, network analysis, randomized controlled trials, psychedelic research, symptom-level outcomes, precision psychiatry, clinical trial design, depression symptom networkshttps://mindmedicinelaw.com/briefing/ketamine-symptom-level-efficacy-in-trd-pooled-rct-analysis-20260926-45395The Psychedelic Journalen2026-09-29T22:04:26.931089+00:00Ketamine Symptom-Level Efficacy in TRD: Pooled RCT Analysisketamine, treatment-resistant depression, symptom-level analysis, randomized controlled trials, network analysis, psychiatric policy, regulatory implications, clinical trial design, personalized psychiatryhttps://mindmedicinelaw.com/briefing/filament-health-expands-psilocybin-supply-for-italian-trd-trial-20260925-45661The Psychedelic Journalen2026-09-30T22:06:38.374656+00:00Filament Health Expands Psilocybin Supply for Italian TRD Trialfilament health, psilocybin, treatment-resistant depression, italy, clinical trials, gmp supply, tempo trial, european regulation, pharma-academic partnershiphttps://mindmedicinelaw.com/briefing/prolonged-psychological-distress-after-lsd-case-report-insights-for-clinical-and-20260924-44724The Psychedelic Journalen2026-09-29T15:05:30.496413+00:00Prolonged Psychological Distress After LSD: Case Report Insights for Clinical and Public Health Policylsd adverse effects, psychedelic harm reduction, clinical trial screening, psychiatric vulnerability, set and setting, alcohol and psychedelics, case report, public health policyhttps://mindmedicinelaw.com/briefing/no-subacute-ketamine-effect-on-reward-processing-implications-for-trial-design-20260924-44774The Psychedelic Journalen2026-09-29T15:05:21.578396+00:00No Subacute Ketamine Effect on Reward Processing: Implications for Trial Designketamine, reward processing, fMRI, clinical trial design, subacute effects, healthy adults, mood disorders, pharmacokinetics, neural biomarkershttps://mindmedicinelaw.com/briefing/temporal-structure-modulates-psychedelic-experience-new-evidence-20260924-44794The Psychedelic Journalen2026-09-29T15:05:09.624270+00:00Temporal Structure Modulates Psychedelic Experience: New Evidencepsychedelic experience, temporal structure, clinical trial design, neuroscience, subjective effects, intervention timing, therapeutic protocols, FDA, research methodologyhttps://mindmedicinelaw.com/briefing/ketamine-use-during-spine-surgery-implications-for-opioid-reduction-policies-20260923-44885The Psychedelic Journalen2026-09-29T15:06:03.930269+00:00Ketamine Use During Spine Surgery: Implications for Opioid Reduction Policiesketamine, lumbar spine surgery, chronic opioid use, opioid-use disorder, perioperative pain management, retrospective study, policy implications, clinical protocols, enhanced recovery, opioid stewardshiphttps://mindmedicinelaw.com/briefing/trehalose-from-psilocybe-preclinical-antidepressant-effects-20260923-44731The Psychedelic Journalen2026-09-29T15:05:52.654662+00:00α,α-Trehalose from Psilocybe: Preclinical Antidepressant Effectsα,α-trehalose, psilocybe cubensis, preclinical antidepressant, anxiolytic effects, 5-HT1A receptor, non-psychedelic metabolites, mental health therapeutics, drug development, regulatory implicationshttps://mindmedicinelaw.com/briefing/attachment-based-interventions-and-intergenerational-substance-use-risk-implicat-20260923-44743The Psychedelic Journalen2026-09-29T15:05:40.123328+00:00Attachment-Based Interventions and Intergenerational Substance Use Risk: Implications for Policy and Practiceattachment-based interventions, parental substance use, intergenerational risk, care-experienced populations, public health policy, family-oriented treatment, attachment security, substance use prevention, systematic review, child welfarehttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-milestone-phase-2-mdd-trial-and-trd-supply-in-canada-20260923-45240The Psychedelic Journalen2026-09-29T15:04:33.323104+00:00Optimi Health's Psilocybin Milestone: Phase 2 MDD Trial and TRD Supply in Canadaoptimi health, psilocybin, canada, health canada, gmp production, phase 2 clinical trial, major depressive disorder, treatment-resistant depression, psychedelic supply chain, regulatory policyhttps://mindmedicinelaw.com/briefing/early-data-from-uk-s-first-pediatric-ketamine-uropathy-clinic-20260922-45483The Psychedelic Journalen2026-09-30T15:05:32.932803+00:00Early Data from UK’s First Pediatric Ketamine Uropathy Clinicketamine-induced uropathy, pediatric substance misuse, uk public health, youth drug trends, clinical guidelines, recreational ketamine, sociodemographic risk factors, policy response, harm reduction, adolescent healthhttps://mindmedicinelaw.com/briefing/patient-factors-and-subanesthetic-ketamine-in-pacu-clinical-insights-20260922-45074The Psychedelic Journalen2026-09-30T15:05:18.945170+00:00Patient Factors and Subanesthetic Ketamine in PACU: Clinical Insightssubanesthetic ketamine, postanesthesia care unit, perioperative pain management, patient selection, risk stratification, psychiatric comorbidity, opioid tolerance, clinical protocols, pharmacovigilancehttps://mindmedicinelaw.com/briefing/debate-over-subjective-measures-in-ketamine-and-psilocybin-trials-20260922-44734The Psychedelic Journalen2026-09-30T15:05:07.286684+00:00Debate Over Subjective Measures in Ketamine and Psilocybin Trialssubjective effects, ketamine, psilocybin, clinical trials, measurement tools, meta-analysis, regulatory science, psychotherapy, FDA, methodological rigorhttps://mindmedicinelaw.com/briefing/methodological-critique-of-ketamine-subjective-effects-studies-20260922-44735The Psychedelic Journalen2026-09-30T15:04:55.987731+00:00Methodological Critique of Ketamine Subjective Effects Studiesketamine, subjective effects, methodological flaws, psychedelic-assisted therapy, clinical trial design, meta-analysis, research standards, FDA, validated measures, regulatory implicationshttps://mindmedicinelaw.com/briefing/comorbidity-of-bipolar-disorder-in-cluster-headache-clinical-and-research-implic-20260922-44736The Psychedelic Journalen2026-09-30T15:04:43.690143+00:00Comorbidity of Bipolar Disorder in Cluster Headache: Clinical and Research Implications (Netherlands, 2026)cluster headache, bipolar disorder, comorbidity, psychedelic clinical trials, psychiatric screening, familial aggregation, illicit drug use, patient selection, netherlands, circadian rhythmhttps://mindmedicinelaw.com/briefing/ptsd-fear-circuit-insights-implications-for-psychedelic-interventions-20260922-44745The Psychedelic Journalen2026-09-29T22:06:21.361275+00:00PTSD Fear Circuit Insights: Implications for Psychedelic Interventionsptsd neural circuitry, fear circuit, exposure therapy, propranolol, psychedelic-assisted therapy, mdma, psilocybin, treatment gaps, biomarkers, clinical trial designhttps://mindmedicinelaw.com/briefing/psilocybin-ethocybin-heighten-aversive-memory-in-stressed-mice-20260922-44764The Psychedelic Journalen2026-09-29T22:06:09.017008+00:00Psilocybin, Ethocybin Heighten Aversive Memory in Stressed Micepsilocybin, ethocybin, aversive memory, preclinical study, chronic social stress, pavlovian conditioning, psychedelic therapy, emotional processing, clinical trial risk, neuroplasticityhttps://mindmedicinelaw.com/briefing/glutamatergic-mechanisms-in-depression-schizophrenia-and-addiction-implications--20260922-44767The Psychedelic Journalen2026-09-29T22:05:57.086489+00:00Glutamatergic Mechanisms in Depression, Schizophrenia, and Addiction: Implications for Psychedelic Researchglutamate, psychedelics, depression, schizophrenia, addiction, biomarkers, clinical trial design, ketamine, translational neurosciencehttps://mindmedicinelaw.com/briefing/self-inquiry-as-a-neurophenomenological-tool-implications-for-psychedelic-resear-20260922-44733The Psychedelic Journalen2026-09-29T22:05:42.194572+00:00Self-Inquiry as a Neurophenomenological Tool: Implications for Psychedelic Researchself-inquiry, consciousness research, neurophenomenology, psychedelic therapy, nondual awareness, minimal self, clinical trials, advaita vedanta, subjective experiencehttps://mindmedicinelaw.com/briefing/dmt-harmine-eeg-signatures-implications-for-psychedelic-biomarkers-20260922-44829The Psychedelic Journalen2026-09-29T22:05:28.959464+00:00DMT/Harmine EEG Signatures: Implications for Psychedelic Biomarkersdmt, harmine, eeg biomarkers, psychedelic research, clinical trial design, regulatory science, ayahuasca, neurophysiology, biomarker developmenthttps://mindmedicinelaw.com/briefing/methodological-challenges-in-assessing-ketamine-s-subjective-effects-20260922-44889The Psychedelic Journalen2026-09-29T15:06:17.839258+00:00Methodological Challenges in Assessing Ketamine's Subjective Effectsketamine subjective effects, clinical trial methodology, psychedelic research, patient-reported outcomes, regulatory science, measurement standardization, FDA, EMA, psychometrics, risk-benefit analysishttps://mindmedicinelaw.com/briefing/phenomenological-frameworks-in-psychedelic-therapy-implications-for-research-and-20260921-44741The Psychedelic Journalen2026-09-30T15:06:17.868736+00:00Phenomenological Frameworks in Psychedelic Therapy: Implications for Research and Ethicsphenomenology, psychedelic therapy, merleau-ponty, mystical experience, embodiment, clinical trial design, ethics, depression, subjective experience, regulatory policyhttps://mindmedicinelaw.com/briefing/serotonin-1b-receptor-new-target-in-depression-anxiety-research-20260921-44830The Psychedelic Journalen2026-09-30T15:06:04.770646+00:00Serotonin 1B Receptor: New Target in Depression & Anxiety Researchserotonin 1b receptor, depression treatment, anxiety therapy, psychedelic research, serotonergic pathways, clinical trials, drug development, mental health policy, regulatory sciencehttps://mindmedicinelaw.com/briefing/timing-deficits-in-schizophrenia-neurobiological-insights-and-psychedelic-resear-20260921-44738The Psychedelic Journalen2026-09-30T15:05:47.518340+00:00Timing Deficits in Schizophrenia: Neurobiological Insights and Psychedelic Research Implicationsschizophrenia, time processing, dopaminergic dysfunction, gabaergic system, nmda receptor, psychedelic research, biomarkers, clinical trials, cognitive symptoms, neurobiologyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-gaba-and-glutamate-in-depression-meta-analysis-insights-20260921-45356The Psychedelic Journalen2026-09-29T22:05:17.527724+00:00Ketamine’s Impact on GABA and Glutamate in Depression: Meta-Analysis Insightsketamine, depression, gaba, glutamate, magnetic resonance spectroscopy, biomarkers, rapid-acting antidepressants, clinical trials, fda regulation, psychiatric drug developmenthttps://mindmedicinelaw.com/briefing/ayahuasca-and-early-life-stress-preclinical-insights-for-neuroscience-and-policy-20260919-44832The Psychedelic Journalen2026-09-30T15:06:29.249826+00:00Ayahuasca and Early-Life Stress: Preclinical Insights for Neuroscience and Policyayahuasca, early-life stress, preclinical research, psychedelic neuroscience, rat model, behavioral outcomes, neurochemical effects, clinical trial design, policy implications, translational challenges